Quazepam: profile and news

Neurocrine's FDA Rejection Bodes Well For Sepracor  16 May 2006
..."With Indiplon being kept off the shelves, we believe Questcor's ability to successfully market Doral (quazepam) to neurologists increases significantly," he ... - Forbes

Questcor Announces the Acquisition of Doral(R) (quazepam) ...  May 5, 2006
Questcor Pharmaceuticals, Inc. (AMEX:QSC) todayannounced the acquisition of US rights to Doral(R) (quazepam), anon-narcotic, selective benzodiazepine receptor ... - Finanzen.net,

Questcor Announces the Acquisition of Doral(R) (quazepam) ...  May 5, 2006
...(AMEX:QSC) today announced the acquisition of US rights to Doral(R) (quazepam), a non-narcotic, selective benzodiazepine receptor agonist that is indicated for ... - Business Wire (press release),

Questcor Announces the Acquisition of Doral(R) (quazepam) ...  May 5, 2006
Questcor Pharmaceuticals, Inc. (AMEX:QSC) today announced the acquisition of US rights to Doral(R) (quazepam), a non-narcotic, selective benzodiazepine ... - Genetic Engineering News,

Questcor to Webcast Annual Meeting Presentation  May 15, 2006
...corticotropin injection), an injectable drug indicated for the treatment of exacerbations associated with Multiple Sclerosis and Doral(R) (quazepam) that is ... - Genetic Engineering News,

Questcor Announces Financial Results for the First Quarter of 2006 ...  May 9, 2006
..."Moving forward, as demonstrated by our recent acquisition of US rights to Doral(R) (quazepam), our focus will continue to be on growing and capitalizing on ... - PharmaLive.com (press release),

Questcor licenses US Doral rights for $4M  May 8, 2006
Questcor Pharmaceuticals has acquired the domestic rights to the insomnia drug Doral (quazepam) from fellow USA-based MedPointe for $2.5 million in cash and a ... - Therapeutics Daily (subscription) (press release),